The Goldman Sachs Group Cuts HealthEquity (NASDAQ:HQY) Price Target to $94.00

HealthEquity (NASDAQ:HQY) had its price objective decreased by The Goldman Sachs Group from $107.00 to $94.00 in a research note published on Thursday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Royal Bank of Canada boosted their price objective on shares of HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. KeyCorp dropped their target price on shares of HealthEquity from $120.00 to $110.00 and set an “overweight” rating on the stock in a report on Monday, March 24th. Raymond James upgraded shares of HealthEquity from an “outperform” rating to a “strong-buy” rating and reduced their price target for the company from $120.00 to $115.00 in a report on Tuesday, March 25th. JMP Securities boosted their price target on HealthEquity from $105.00 to $107.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 10th. Finally, Mizuho assumed coverage on shares of HealthEquity in a report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 target price for the company. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $112.23.

HealthEquity Trading Down 2.1 %

HQY opened at $86.96 on Thursday. HealthEquity has a one year low of $65.01 and a one year high of $115.59. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. The stock has a market cap of $7.52 billion, a price-to-earnings ratio of 79.78, a P/E/G ratio of 1.60 and a beta of 0.62. The stock’s 50 day moving average price is $103.63 and its 200-day moving average price is $96.06.

Insider Activity at HealthEquity

In other news, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the sale, the director now directly owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.20% of the stock is currently owned by insiders.

Institutional Trading of HealthEquity

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wealthfront Advisers LLC bought a new position in shares of HealthEquity during the fourth quarter valued at approximately $10,304,089,000. T. Rowe Price Investment Management Inc. bought a new stake in HealthEquity during the fourth quarter worth approximately $78,107,000. Norges Bank acquired a new position in HealthEquity during the fourth quarter worth about $74,701,000. Wasatch Advisors LP raised its holdings in shares of HealthEquity by 6.6% in the 3rd quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock worth $635,065,000 after purchasing an additional 483,269 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of HealthEquity during the fourth quarter worth $45,728,000. 99.55% of the stock is owned by institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.